These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35837290)

  • 1. Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury.
    Howard ZM; Gomatam CK; Piepho AB; Rafael-Fortney JA
    Front Pharmacol; 2022; 13():942660. PubMed ID: 35837290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury.
    Howard ZM; Rastogi N; Lowe J; Hauck JS; Ingale P; Gomatam C; Gomez-Sanchez CE; Gomez-Sanchez EP; Bansal SS; Rafael-Fortney JA
    Am J Physiol Cell Physiol; 2022 Mar; 322(3):C354-C369. PubMed ID: 35044859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy.
    Howard ZM; Gomatam CK; Rabolli CP; Lowe J; Piepho AB; Bansal SS; Accornero F; Rafael-Fortney JA
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
    Chadwick JA; Hauck JS; Gomez-Sanchez CE; Gomez-Sanchez EP; Rafael-Fortney JA
    Physiol Genomics; 2017 Jun; 49(6):277-286. PubMed ID: 28432191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-type specific effects of mineralocorticoid receptor gene expression suggest intercellular communication regulating fibrosis in skeletal muscle disease.
    Gomatam CK; Ingale P; Rodriguez G; Munger S; Pomeranets R; Krishna S; Lowe J; Howard ZM; Rafael-Fortney JA
    Front Physiol; 2024; 15():1322729. PubMed ID: 38737833
    [No Abstract]   [Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.
    Lowe J; Kolkhof P; Haupt MJ; Peczkowski KK; Rastogi N; Hauck JS; Kadakia FK; Zins JG; Ciccone PC; Smart S; Sandner P; Raman SV; Janssen PML; Rafael-Fortney JA
    ESC Heart Fail; 2020 Dec; 7(6):3983-3995. PubMed ID: 32945624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonists improve membrane integrity independent of muscle force in muscular dystrophy.
    Hauck JS; Lowe J; Rastogi N; McElhanon KE; Petrosino JM; Peczkowski KK; Chadwick AN; Zins JG; Accornero F; Janssen PML; Weisleder NL; Rafael-Fortney JA
    Hum Mol Genet; 2019 Jun; 28(12):2030-2045. PubMed ID: 30759207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.
    Chadwick JA; Bhattacharya S; Lowe J; Weisleder N; Rafael-Fortney JA
    Am J Physiol Cell Physiol; 2017 Feb; 312(2):C155-C168. PubMed ID: 27881412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.
    Chadwick JA; Swager SA; Lowe J; Welc SS; Tidball JG; Gomez-Sanchez CE; Gomez-Sanchez EP; Rafael-Fortney JA
    Hum Mol Genet; 2016 Dec; 25(23):5167-5177. PubMed ID: 27798095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury.
    Hauck JS; Howard ZM; Lowe J; Rastogi N; Pico MG; Swager SA; Petrosino JM; Gomez-Sanchez CE; Gomez-Sanchez EP; Accornero F; Rafael-Fortney JA
    Front Physiol; 2019; 10():1324. PubMed ID: 31736768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
    Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
    J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
    Heier CR; Yu Q; Fiorillo AA; Tully CB; Tucker A; Mazala DA; Uaesoontrachoon K; Srinivassane S; Damsker JM; Hoffman EP; Nagaraju K; Spurney CF
    Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30745312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise.
    Lowe J; Kadakia FK; Zins JG; Haupt M; Peczkowski KK; Rastogi N; Floyd KT; Gomez-Sanchez EP; Gomez-Sanchez CE; Elnakish MT; Rafael-Fortney JA; Janssen PML
    J Neuromuscul Dis; 2018; 5(3):295-306. PubMed ID: 30010143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.
    Chadwick JA; Hauck JS; Lowe J; Shaw JJ; Guttridge DC; Gomez-Sanchez CE; Gomez-Sanchez EP; Rafael-Fortney JA
    FASEB J; 2015 Nov; 29(11):4544-54. PubMed ID: 26178166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
    Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
    PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
    Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
    Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
    Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.